Penpulimab

Generic Name
Penpulimab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
2350298-92-7
Unique Ingredient Identifier
IBS1BZ4E4I
Indication

适用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤成人患者。

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

First Posted Date
2024-07-24
Last Posted Date
2024-07-24
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
528
Registration Number
NCT06516978

TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.

First Posted Date
2024-03-07
Last Posted Date
2024-08-06
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Target Recruit Count
3
Registration Number
NCT06297642
Locations
🇨🇳

Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China

🇨🇳

The Second People's Hospital of Hefei, Hefei, Anhui, China

🇨🇳

Lu'an People's Hospital of Anhui Province, Lu'an, Anhui, China

and more 2 locations

Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer

First Posted Date
2023-09-25
Last Posted Date
2023-09-25
Lead Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Target Recruit Count
177
Registration Number
NCT06051851
Locations
🇨🇳

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China

A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody

First Posted Date
2023-09-21
Last Posted Date
2023-09-21
Lead Sponsor
Degan Lu
Target Recruit Count
52
Registration Number
NCT06048315

The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment

First Posted Date
2023-06-02
Last Posted Date
2023-06-02
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
5
Registration Number
NCT05885399
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, China

Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer

Phase 2
Not yet recruiting
Conditions
Breast Cancer
Interventions
Drug: Disitamab Vedotin
Drug: Penpulimab
First Posted Date
2023-02-13
Last Posted Date
2023-02-13
Lead Sponsor
West China Hospital
Target Recruit Count
20
Registration Number
NCT05726175
Locations
🇨🇳

West China Hospital, Sichuan University, Chengdu, Chengdu, Sichuan, China, China

Penpulimab in Maintenance Therapy in Lymphoma

Not yet recruiting
Conditions
Lymphoma
First Posted Date
2023-01-11
Last Posted Date
2023-01-11
Lead Sponsor
WEI XU
Target Recruit Count
167
Registration Number
NCT05680038

SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer

First Posted Date
2022-10-12
Last Posted Date
2022-10-12
Lead Sponsor
Ruijin Hospital
Target Recruit Count
55
Registration Number
NCT05576480

A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer.

First Posted Date
2022-08-09
Last Posted Date
2024-05-09
Lead Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Target Recruit Count
66
Registration Number
NCT05493995
Locations
🇨🇳

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

First Posted Date
2022-08-03
Last Posted Date
2022-08-03
Lead Sponsor
Peking University Third Hospital
Target Recruit Count
32
Registration Number
NCT05485350
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy